Antithrombotic Drugs: Part II

The defibrinating agent ancrod has had limited clinical trial, but appears to give no advantages over heparin.Intravenous infusion of dextran, a glucose polymer, has been shown to have an anti-thrombotic effect in many experimental models of thrombosis. However, the evidence that dextran is a clinically valuable antithrombotic drug is conflicting. A number of controlled randomised studies have shown that dextran can prevent postoperative venous …